Pharmaceutical company Jubilant Life Sciences reported 9% increase in income from operations to Rs. 1,358 crore in the April-June quarter from Rs. 1,240 crore in the year-ago period.
During the first quarter, the company’s income from operations from the pharmaceuticals segment was Rs. 651 crore, a growth of 2% year-on-year.
“Going forward, we expect strong operational performance in pharmaceuticals due to new product launches, geographic expansion and higher capacity utilisation,” said Shyam S Bhartia, chairman and MD, and Hari S Bhartia, co-chairman and MD, Jubilant Life Sciences.